Opendata, web and dolomites

GONDOLA SIGNED

Automated Mechanical Peripheral Stimulation for motor rehabilitation in people living with Parkinson’s Disease (PD)

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GONDOLA project word cloud

Explore the words cloud of the GONDOLA project. It provides you a very rough idea of what is the project "GONDOLA" about.

effectiveness    basic    walking    regulate    neurotransmitter    invasive    annual    fluidity    regard    priorities    treatment    peripheral    safety    disorder    advancing    movements    economic    amps    freezing    prevalence    delivers    inability    benefits    motor    costly    mechanical    families    hesitation    living    falls    symptoms    efficacy    documented    patients    regulates    afferent    physical    parkinson    stages    feet    made    quality    named    life    ourselves    medical    brain    balance    2004    disabled    generator    lessening    device    neurodegenerative    society    treating    gait    self    medications    spending    stimulation    characterised    ideal    functioning    undermine    individuals    dopamine    cure    independence    skills    confidence    2040    body    neurostimulations    time    nervous    ninds    neurostimulation    disease    7b    pattern    strategy    points    10m    aligned    automated    clinical    people    portable    spinal    causing    pd    more    nih    slowness    motions    substantial    risk    burden    reducing    gondolatm    double    inputs    globally    induce    mechanism    therapies    person    central    recommendations    cord   

Project "GONDOLA" data sheet

The following table provides information about the project.

Coordinator
GONDOLA MEDICAL TECHNOLOGIES SA 

Organization address
address: CORSO ELVEZIA 9 A
city: LUGANO
postcode: 6900
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Project website https://www.gondola-parkinson.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GONDOLA MEDICAL TECHNOLOGIES SA CH (LUGANO) coordinator 50˙000.00

Map

 Project objective

Parkinson’s disease (PD) is a neurodegenerative brain disorder, characterised by the inability of a person’s brain to produce a neurotransmitter called dopamine, lessening a person’s ability to regulate body motions. PD affects 10m people globally, its prevalence is expected to double by 2040. There is no cure for PD, current therapies focus on treating symptoms that undermine patients’ quality of life. Costs associated with PD are higher than its prevalence, causing substantial economic burden on individuals, families and society. In 2004, the annual spending in Europe on PD was €10.7b. As costly as they are, these therapies improve motor symptoms in the early stages of PD, but over time, patients have more and more reduced response to medications and become more disabled. Thus, they cannot be considered as ideal with regard to efficacy, long-term effectiveness and safety. NINDS (part of the US NIH) set recommendations addressing Gait as one of the 3 top priorities for advancing basic clinical research on PD. We have aligned ourselves with NINDS’ strategy through development of GondolaTM. GondolaTM is a portable medical device made for people living with PD. It delivers a non-invasive neurostimulation treatment named Automated Mechanical Peripheral Stimulation (AMPS). It is based on physical neurostimulations of specific points in both feet, which allow to increase the afferent inputs from the peripheral nervous system to the spinal cord, and induce a better functioning of the central pattern generator (the mechanism that regulates movements in the body). Four clinical studies have documented that AMPS is effective in improving motor skills in PD, particularly slowness of movements and freezing of gait. Users have derived the following benefits from the device: Reduced Freezing of gait, gait hesitation, slowness of movements, improved independence, self-confidence, fluidity in walking and balance, reducing the risk of falls and improving the quality of life.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GONDOLA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GONDOLA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More